Congenital heart defects (CHD) represent the most common congenital malformations globally and constitute a leading cause of neonatal mortality, with early maternal risk factors playing significant ...

OS of 8.9 months versus 5.8 months with trifluridine/tipiracil alone, supporting phase III ...

AI use in federal health agencies has been garnering increasing interest due to its potential to expedite processes and improve efficiency.

Not all of Marvel's mutants are superpowered, or super glamorous; let's dig deeper into the most unfortunate mutations in ...

Background Although the increased risk of cardiovascular disease in patients with SLE is well-documented, effective tools for risk stratification remain elusive. This study sought to explore the ...

A protein best known for its role in Parkinson’s disease can accelerate Alzheimer’s-related brain changes by up to 20 times in patients who carry elevated levels of both pathologies, according to new ...

Background Cardiovascular disease (CVD) is the leading cause of mortality worldwide, while depression is highly prevalent in this patient population and has long been regarded as an independent risk ...

It is expected that the board, which for a time will advise a unit within the council, will spin off eventually to work with ...

Objective Biologics for systemic lupus erythematosus (SLE) demonstrate variable treatment responses across trials. We evaluated baseline biomarkers as predictors of response to guide personalised ...

A long-term study of 2,766 women in the Women’s Health Initiative Memory Study found that higher baseline plasma p-tau217 levels were associated with a greater risk of developing mild cognitive ...

This study presents valuable findings for identifying biotypes of depression patients using white matter measures, which are under-utilised and under-appreciated in current biological and ...

The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...